Lion Biotech Gets Some Claims Trimmed In Investor Dispute
A California federal judge has dismissed two of six claims in a proposed class action against Lion Biotechnologies Inc., leaving in place allegations that it artificially inflated its stock price by...To view the full article, register now.
Already a subscriber? Click here to view full article